Gilead Sciences (GILD) Rating Kept
Mizuho Securities currently has a $95.0 price target on the $ market cap company or 18.54 % upside potential. In analysts note issued on Monday morning, Gilead Sciences (GILD) stock had its “Buy” Rating reiterated by research professionals at Mizuho Securities.
GILD is now trading 0.00% lower at $0.00 as of 2:04 PM New York time. Gilead Sciences’s stock is 0% over the last 200 days. It has underperformed the S&P 500 Index, which has risen 6.00% over the same time.
Out of 19 brokers covering Gilead Sciences, 16 rate it a Buy, 9 indicate a Hold while 0 suggest a Sell. The highest target is $135 and the lowest is $81 according to Thomson/First Call. The 12-month mean target is $111.05, which means upside potential of ∞% over the current price.
Domini Social Investments Llc had the most significant stake with ownership of 4,906 shares as of q2 2015 for 17.99% of the equity exposure. Cabot is another quite bullish institutional investor who is possessing 147,130 shares of Gilead Sciences or 9.41% of their equity exposure. In addition, Hollow Brook Wealth Management Llc have 8.91% of their equity exposure invested in the company for 190,499 shares. The Singapore-based fund Temasek Holdings (Private) Ltd disclosed it had purchased a stake worth about 8.86% of the institutional investor’s stock portfolio in Gilead Sciences. The Massachusetts-based fund Tekla Capital Management Llc is also positive about the stock, possessing 13.83 million shares or 8.09% of their equity exposure.
Gilead Sciences (GILD) closed at $0 yesterday. A total of shares of the company’s stock traded hands. This is down from average of shares. Gilead Sciences has a 52 week low of $0.00 and a 52 week high of $0. The company has a market cap of $ and a P/E ratio of 0.
Get the latest Gilead Sciences (GILD) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.